

## Apothecary by Design (ABD) Appoints Richard Friedman Executive Chairman

\* BelHealth Operating Partner

\*Former CEO of BioScrip & Chairman of Aureus Health Services

Portland, ME – July 20, 2016 – Apothecary by Design (ABD), a leading distributor of specialty pharmaceuticals and a BelHealth Investment Partners LLC ("BelHealth") portfolio company, announced the appointment of Richard Friedman as Executive Chairman. ABD is executing its strategic plan to become a leading, national, Women's Health specialty pharmacy.

Mr. Friedman is a BelHealth Operating Partner and former Chairman of Aureus Healthcare Services, a past BelHealth portfolio company. Mr. Friedman has more than 30 years of experience in the healthcare industry with a focus in specialty pharmacy, generic pharmaceuticals, pharmacy benefit management (PBM) and infusion. Prior to Aureus, Mr. Friedman served as Chairman and CEO of BioScrip Inc., a publicly traded specialty pharmacy and PBM (NASDAQ: BIOS). During his tenure at BioScrip Inc., he was instrumental in growing the company into a \$1.7 billion business and positioning it for the eventual sale of its specialty pharmacy operations to Walgreens in May 2012.

Mr. Friedman was Chairman and CEO of MIM Corporation (NASDAQ: MIMS), the predecessor to BioScrip and a specialty pharmaceutical and benefit fulfillment organization that collaborates with healthcare providers and sponsors to control prescription drug costs. Mr. Friedman took MIM public in 1996 and oversaw a number of mergers and acquisitions, including its acquisition of Chronimed in 2004, which created BioScrip. Earlier, Mr. Friedman was a pioneer in the generic drug marketplace at companies including Zenith Laboratories Inc., a leading manufacturer and distributor of generic drugs, and Goldline Laboratories.

Mark McAuliffe, CEO of ABD, stated, "We are thrilled to have Rich join our team as Executive Chairman. His prior successes and substantial experience in the specialty pharmacy industry will be invaluable to ABD. We are well on our way to executing our strategic growth plan and Rich expanding his role from Board member to Executive Chairman will accelerate our timeline to achieve this plan."

Harold S. Blue, BelHealth Founder and Managing Partner said, "We are pleased Rich has agreed to become Executive Chairman of ABD. He will be instrumental in building and mentoring the Executive team and driving business development, which will lead to significant growth. Rich's substantial specialty pharmacy expertise will help greatly in replicating our past successes."

## **About Apothecary by Design**

Headquartered in Portland, Maine, Apothecary by Design is a specialty pharmacy focused on Women's Health, Infectious Diseases and Autoimmune Disorders. ABD services fertility and other specialty patients nationally from distribution hubs in Portland, Maine and Warrenville, Illinois. Apothecary by Design offers compassionate care to thousands of patients as well as clinical services and support to prescribers, payors and manufacturers.



## **About BelHealth Investment Partners**

BelHealth Investment Partners ("BelHealth"), based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm typically invests \$20-50 million per platform company across three healthcare segments: Services, Products and Distribution.

For further information: Apothecary by Design: www.apothecarybydesign.com BelHealth: www.belhealth.com

<u>Contact:</u> *Apothecary by Design:* Mark McAuliffe (207) 899-0663 ext. 3500 *BelHealth:* Inder Tallur (347) 308-7018